Drug interaction (40. Drug interactions in pulmonary arterial hypertension treatment)
نویسندگان
چکیده
منابع مشابه
Imatinib for Pulmonary Arterial Hypertension - Wonder Drug or Killer Drug?
tinib showed significant improvement in hemodynamics and physical capacity after 24 months of therapy [7] . Based on these data and independent of any interests on the part of the pharmaceutical industry, pulmonary hypertension specialists in several countries have offered open-label imatinib to their PAH patients as a palliative treatment, but, unfortunately, with little in the way of publishe...
متن کاملDrug Therapy in Patients with Chronic Thromboembolic Pulmonary Hypertension
Background: Chronic Thromboembolic Pulmonary Hypertension (CTEPH) results from the obstruction of predominantly major pulmonary vessels by organized blood clots and is one of the causes of pulmonary hypertension. The disease is still underdiagnosed and the true prevalence is not clear. The objective of this study was to determine the clinical characteristics and current management of patients w...
متن کاملDrug interactions in hypertension.
Interactions between drugs and antihypertensive agents can result in either increased or decreased antihypertensive effects. These interactions may be pharmacokinetic or pharmacodynamic in type, resulting in either altered plasma drug concentrations or altered drug effects at similar plasma concentrations. Drugs may limit the absorption of antihypertensive agents, alter their metabolism through...
متن کاملSignificant drug interactions in dermatology
Systemic drugs have been used widely in the treatment of many skin diseases. Although dermatologists are familiar with the guidelines of selecting appropriate patients and prescribing systemic drugs, their knowledge about the side effects and significant interactions of systemic drugs used in dermatology is more limited. So a short review on important drug interactions seems to be useful. Some ...
متن کاملShort-Term Drug-Drug Interaction between Sildenafil and Bosentan under Long-Term Use in Patients with Pulmonary Arterial Hypertension
Sildenafil and bosentan are often co-administered for pulmonary arterial hypertension (PAH) treatment. The plasma concentration of sildenafil can be decreased by half if co-administered with bosentan. Many patients take these agents simultaneously in the morning and the evening. The aim of this study was to examine the pharmacokinetics of sildenafil which was interfered with bosentan administra...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Okayama Igakkai Zasshi (Journal of Okayama Medical Association)
سال: 2017
ISSN: 0030-1558,1882-4528
DOI: 10.4044/joma.129.187